Skip to content

Search

Getting through to young people on sun safety and vaping

Researchers from The Kids Research Institute Australia and Cancer Council WA will team up on two projects aimed at identifying the most effective public health messaging for young people around SunSmart behaviours and how to stop vaping.

Infant study shines new light on eczema prevention

A study led by The Kids Research Institute Australia has suggested vitamin D supplementation in babies is no match for sunlight when it comes to preventing eczema.

Vitamin D deficiency linked to childhood asthma

Researchers at The Kids Research Institute Australia have found children with vitamin D deficiency are more likely to develop asthma.

Recommendations for Sun Protection in Children and Young People: A Systematic Review of Guidelines and Consensus Statements

Ultraviolet radiation is the leading preventable cause of skin cancer, and early-life exposure increases long-term risk. Despite this, guidelines on sun protection for children and young people are inconsistent. 

Modelling vitamin D food fortification among Aboriginal and Torres Strait Islander peoples in Australia

Low vitamin D intake and prevalence of serum 25-hydroxyvitamin D concentration <50 nmol/L among Aboriginal and Torres Strait Islander peoples highlight a need for public health strategies to improve vitamin D status. Since few foods contain naturally occurring vitamin D, food fortification could be a suitable strategy. We aimed to model vitamin D food fortification scenarios among Aboriginal and Torres Strait Islander peoples.

Insights from a trial of narrowband UVB for early multiple sclerosis

There is a greater prevalence of multiple sclerosis (MS), a neurological autoimmune condition, in populations living further from the equator, hypothesised to be due to reduced sunlight exposure. There exists a proven sunlight surrogate therapy for dermatological inflammatory conditions, in the form of narrowband NB-UVB phototherapy. Yet, there is a paucity of randomized trials of the therapeutic delivery of NB-UVB beyond dermatology for conditions with a systemic inflammatory component.